顺铂联合胸腔持续热灌注治疗肺癌胸水的临床研究

Cisplatin Combined with Continuous Hyperthermic Pleural Perfusion (CHPP) for Lung Caner-induced Pleural Effusion

目的:观察持续热灌注加化疗药顺铂(DDP)治疗肺癌胸水的有效性及不良反应。方法:60例肺癌胸水患者非随机分为顺铂联合胸腔持续热灌注组(治疗组)和单纯顺铂胸腔灌注化疗组(对照组),每组各30例。对2组生存期、胸水的近期疗效、生活质量变化、不良反应进行观察。结果:治疗组和对照组的中位生存期分别为10.4月和6.2月,有效率分别为83.3%和56.7%(P>0.01),治疗组不良反应无加重,对照组不良反应较重。结论:DDP持续热灌注治疗肺癌胸水,能够提高疗效,延长生存期,且不增加不良反应,值得临床推广。

OBJECTIVE： To investigate the efficacy and adverse effects of continued hyperthermic pleural perfusion（CHPP） plus cisplatin（DDP） for lung cancer-induced plural effusion. METHODS： Sixty patients with lung cancer associated with pleural effusion were randomized into either treatment group receiving cisplatin combined with CHPP or control group receiving cisplatin（pleural infusion） alone, 30 patients of each. The survival time, short-term efficacy for pleural effusion, quality of life and adverse effects in the two groups were recorded. RESULTS： The median survival time of the treatment group and the control group were 10.4 months and 6.2 months, respectively, and the effective rates were 83.3% and 56.7% , respectively（P 〉 0.01 ）. There was no worsening of adverse effects in the treatment group; however, the adverse reaction in the control group was serious. CONCLUSION： CHPP plus cisplatin improves treatment efficacy and enhances survival yet without increase of adverse effects in patients with lung cancer associated with pleural effusion, thus this therapy thus is worthy of clinical practice.